Close Menu

SEC

The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.

The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.

The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.

The company intends to use the net proceeds to repay at maturity or redeem its $800 million aggregate principal amount of senior notes due in 2020.

Patrick Muraca, the former CEO of Nuclea Biotechnologies and NanoMolecularDx, was already serving a prison term of more than two years.

The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.

Following its IPO in September, the company is expanding its presence with increased product offerings in the pipeline and a renewed focus on reimbursement and R&D. 

In May, the company received a delisting warning from Nasdaq after its stock closed between the minimum $1 per share requirement for 30 days.

Anpac currently offers a test in China for detecting the risk of 26 cancer types using the firm's so-called cancer differentiation analysis technology.

The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators.

Pages